The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Kirin Pharmaceuticals; Lilly Japan; MSD; Novartis
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Shingo Matsumoto
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Riken Genesis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kei Kunimasa
No Relationships to Disclose
 
Masahiro Kodani
No Relationships to Disclose
 
Koichi Nishi
No Relationships to Disclose
 
Taku Nakagawa
No Relationships to Disclose
 
Shunichi Sugawara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Tomohiro Kato
No Relationships to Disclose
 
Jun Sakakibara-Konishi
No Relationships to Disclose
 
Yuichiro Hayashi
Employment - SRL Diagnostics
 
Koji Tsuta
Speakers' Bureau - MSD; Roche
 
Noriko Motoi
Honoraria - Agilent; AstraZeneca; Bristol-Myers Squibb Japan; MSD; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Miraca Life Sciences; MSD
Research Funding - Roche (Inst)
 
Genichiro Ishii
No Relationships to Disclose
 
Koichi Goto
Honoraria - AbbVie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Life Technologies; Lilly; Merck Serono; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Quintiles; RIKEN GENESIS; SRL Diagnostics; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; Loxo; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Riken Genesis; RTI Health Solutions; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Xcoo